lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-24 and is reviewed periodically as new material appears.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Glyceollin synthase is a cytochrome P450 protein containing heme. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate. The systematic name of this enzyme class is 2-(or 4-)dimethylallyl-(6aS,11aS)-3,6a,9-trihydroxypterocarpan,NADPH:oxygen oxidoreductase (cyclizing). The previous enzyme in the pathway to glyceollins, trihydroxypterocarpan dimethylallyltransferase also produces the isomeric compound 4-dimethylallylglycinol. This is also a substrate for glyceollin synthase:
Japan imports US$3.6 million of New Zealand blackcurrants for uses as dietary supplements, snacks, functional food products and as quick-frozen (IQF) produce for culinary production as jams, jellies or preserves.
== SELEX variants and alternative aptamer selection methods == FRELEX was developed in 2016 by NeoVentures Biotechnology Inc to allow the selection of aptamers without immobilizing the target or the oligonucleotide library. Immobilization is a necessary component of SELEX; however, it has the potential to inhibit key epitopes, and thus weaken the likelihood of successful binding, particularly when working with small molecules. FRELEX follows a similar overall methodology to SELEX; however, instead of immobilizing the target, the researcher introduces a series of random and blocker oligonucleotides to an immobilization field before introduction to the target. This allows the researcher to better target small molecules that may be lost during partitioning. It also can be used in some circumstances to select an aptamer library without knowing the target. Most modern aptamer selection methods strive to improve the conventional SELEX aptamer search method. Despite the publication of various methods aimed at increasing the affinity and specificity of aptamers, experimental approaches face limitations in the number and variety of sequences that can be examined and selected. Library capacity for SELEX experiments is practically limited to 1015 candidates, whereas, assuming there is a 4-monomeric repertoire from which pools can be created, there are ~1.6 × 1060 unique sequences in sequence space limited to a 100-residue matrix, which is clearly beyond experimental capabilities.
Moore supports relocating the Federal Bureau of Investigation's headquarters to Prince George's County, describing it as a "personal priority" and a matter of equity. In March 2023, Moore joined Democratic members of Maryland's congressional delegation and Prince George's County Executive Angela Alsobrooks in co-signing a letter to President Joe Biden asking him to get involved in the FBI's headquarters selection process. In November 2023, the General Services Administration announced that it would locate the FBI's new headquarters in Greenbelt, Maryland. In March 2025, however, President Donald Trump blocked the FBI's move to Maryland, saying that the agency should be located in Washington, D.C., as opposed to "liberal" Maryland. In July 2025, after Trump said that he wanted the new FBI headquarters to be the Ronald Reagan Building and International Trade Center in Washington, D.C., Moore signed onto a letter saying that he and other Maryland lawmakers would "be fighting back against this proposal with every tool we have". He later supported a lawsuit against the Trump administration for interfering in the FBI's relocation.
=== Hernia repair === Multi-layered OFM devices, reinforced with synthetic polymer were first described in 2008 and in the scientific literature in 2010. These devices, termed ‘reinforced biologics’ have been designed for applications in the surgical repair of hernia as an alternative to synthetic surgical mesh (a mesh prosthesis). OFM reinforced biologics are distributed in the US by Tela Bio Inc. Clinical studies have shown that OFM reinforced biologics have lower hernia recurrence rates versus synthetic hernia meshes. or biologics such as acellular dermis.
Sources: en.wikipedia.org
=== Available forms === Elagolix is available in the form of Orilissa 150 and 200 mg oral tablets. The 150 mg tablets are light pink, oblong, and film-coated with "EL 150" debossed on one side, while the 200 mg tablets are light orange, oblong, and film-coated with "EL 200" debossed on one side. The inactive ingredients in the tablets include mannitol, sodium carbonate monohydrate, pregelatinized starch, povidone, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and a distinct color additive (carmine high tint in the 150 mg tablets and iron oxide red in the 200 mg tablets).
=== Hygroscopy and fermentation === Honey has the ability to absorb moisture directly from the air, a phenomenon called hygroscopy. The amount of water the honey absorbs is dependent on the relative humidity of the air. Because honey contains yeast, this hygroscopic nature requires that honey be stored in sealed containers to prevent fermentation, which usually begins if the honey's water content rises much above 25%. Honey tends to absorb more water in this manner than the individual sugars allow on their own, which may be due to other ingredients it contains. Fermentation of honey usually occurs after crystallization, because without the glucose, the liquid portion of the honey primarily consists of a concentrated mixture of fructose, acids, and water, providing the yeast with enough of an increase in the water percentage for growth. Honey that is to be stored at room temperature for long periods of time is often pasteurized, to kill any yeast, by heating it above 70 °C (158 °F).
=== 1970s === Israel responded to the Arab Yom Kippur War attack on 6 October 1973 by assembling 13 nuclear weapons in a tunnel under the Negev desert when Syrian tanks were sweeping in across the Golan Heights. On 8 October 1973, Israeli Prime Minister Golda Meir authorized Defense Minister Moshe Dayan to activate the 13 Israeli nuclear warheads and distribute them to Israeli air force units, with the intent that they be used if Israel began to be overrun. On 24 October 1973, as US President Richard Nixon was preoccupied with the Watergate scandal, Henry Kissinger ordered a DEFCON-3 alert preparing American B-52 nuclear bombers for war. Intelligence reports indicated that the USSR was preparing to defend Egypt in its Yom Kippur War with Israel. It had become apparent that if Israel had dropped nuclear weapons on Egypt or Syria, as it prepared to do, then the USSR would have retaliated against Israel, with the US then committed to providing Israeli assistance, possibly escalating to a general nuclear war. By the late 1970s, people in both the United States and the Soviet Union, along with the rest of the world, had been living with the concept of mutual assured destruction (MAD) for about a decade, and it became deeply ingrained into the psyche and popular culture of those countries. On May 18, 1974, India conducted its first nuclear test in the Pokhran test range. The name of the operation was Smiling Buddha, and India termed the test as a "peaceful nuclear explosion." The Soviet Duga early warning over-the-horizon radar system was made operational in 1976.
=== Clinical trials === The US Food and Drug Administration (FDA) approved galcanezumab based on evidence from three clinical trials (Trial 1/NCT02614183, Trial 2/NCT02614196, and Trial 3/NCT02614261) in 2156 adults 18 to 65 years of age with chronic or episodic migraine headaches. Trials were conducted at 318 sites in Asia, Canada, Europe, Israel, Latin America, Puerto Rico, and the United States. Trials one and two enrolled participants with a history of episodic migraine headaches. Participants were assigned to receive galcanezumab or placebo injections once a month for six months. Neither the participants nor the health care providers knew which treatment was being given until after the trial was completed. The benefit of galcanezumab was assessed based on the change from baseline in the number of migraine days per month during the six-month treatment period, comparing participants in the galcanezumab and placebo groups. In two studies involving 1,784 participants who had migraines between 4 and 14 days a month, those treated with galcanezumab had four or five fewer days with migraines per month, compared with two to three fewer days for participants on a placebo injection. Trial three enrolled participants with a history of chronic migraine headaches. Participants were assigned to receive galcanezumab or placebo injection once a month for three months. Neither the participants nor the health care providers knew which treatment was being given until after the trial was completed.
Sources: en.wikipedia.org
According to neo-Darwinian evolution, such mutations should rarely exist as these sequences are functionless and positive selection would not be able to operate. The McDonald–Kreitman test has been used to study selection over long periods of evolutionary time. This is a statistical test that compares polymorphism in neutral and functional sites and estimates what fraction of substitutions have been acted on by positive selection. The test often uses synonymous substitutions in protein coding genes as the neutral component; however, synonymous mutations have been shown to be under purifying selection in many instances.
From late May 1900, the first successes of the Boer guerrilla strategy were at Lindley (where 500 Yeomanry surrendered), and at Heilbron (where a large convoy and its escort were captured) and other skirmishes resulting in 1,500 British casualties in less than ten days. In December 1900, De la Rey and Christiaan Beyers attacked and mauled a British brigade at Nooitgedacht, inflicting 650 casualties. As a result, the British, led by Lord Kitchener, mounted extensive searches for Christiaan de Wet, but without success. However, Boer raids on British army camps and other targets were sporadic and poorly planned, and the nature of the Boer guerrilla war itself had no long-term objectives, with the exception to harass the British. This led to a disorganised pattern of scattered engagements between the British and Boers.
The common oxidation states of rhodium are +3 and +1. Complexes with rhodium in oxidation states 0, +2, and +4 are also well characterized. The few compounds at still higher oxidation states include rhodium pentafluoride, a tetrameric complex with the true formula Rh4F20), and rhodium hexafluoride. Three rhodium oxides are Rh2O3 (a paramagnetic black powder), RhO2 (black when anhydrous but green as a hydrate), and RhO3 (only stable in the gas phase). A rhodium sulfide, Rh17S15, occurs naturally as a rare mineral miassite. Synthetic RhxSy are used as catalysts in for example H2-Br2 fuel cells.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.